Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[27/09/2022]

UCB : FINTEPLA®▼ (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome

https://mb.cision.com/Public/18595/3636902/999776931e930491_800x800ar.png FINTEPLA^=C2=AE=E2=96=BC fenfluramine Approved in Japan for the Treatm= ent of Seizures Associated with Dravet Syndrome =C2=B7 Approval supported by clinical trial data that showed when added to = existing treatment regimens, fenfluramine significantly reduced monthly con= vulsive seizure frequency compared to... See more
 
UCB [BE0003739530/UCB]   
[23/09/2022]

UCB : UCB Media Room: Disposal of own shares

https://mb.cision.com/Public/18595/3635918/b92cf093d562c84f_800x800ar.png Disposal of own shares Brussels Belgium, 23 September 2022 =E2=80=93 20:00 CEST =E2=80=93 Regu= lated information=C2=A0 In accordance with article 8:6 of the Royal Decree executing the Belgian Co= de of Companies and Associations, UCB announces that, following exercises o= f stock options by members of its... See more
 
UCB [BE0003739530/UCB]   
[22/09/2022]

UCB : UCB Media Room: UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

https://mb.cision.com/Public/18595/3634655/97a5454c47e4c409_800x800ar.png UCB presents latest data from generalized myasthenia gravis portfolio at= AANEM meeting =C2=B7 Results presented across UCB=E2=80=99s generalized myasthenia gravis= gMG development program builds the body of evidence around the complexit= ies of gMG=C2=A0 =C2=B7 Presentations to include data from the Phase 3... See more
 
UCB [BE0003739530/UCB]   
[20/09/2022]

UCB : UCB Media Room: EMA Accepts Marketing Authorization Applications for Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis

https://mb.cision.com/Public/18595/3633521/9ede195250bc24e5_800x800ar.png European Medicine Agency Accepts Marketing Authorization Applications fo= r Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis =C2=B7 First regulatory submissions for bimekizumab in psoriatic arthritis = and axial spondyloarthritis worldwide Brussels Belgium, 20th September 2022 =E2=80=93 07:00... See more
 
UCB [BE0003739530/UCB]   
[09/09/2022]

UCB : UCB Media Room: Disposal of own shares

https://mb.cision.com/Public/18595/3628890/b532caec227679a2_800x800ar.png Disposal of own shares Brussels Belgium, 9 September 2022 =E2=80=93 20:00 CEST =E2=80=93 Regul= ated information=C2=A0 In accordance with article 8:6 of the Royal Decree executing the Belgian Co= de of Companies and Associations, UCB announces that on 5 September 2022, i= n accordance with the vesting rules... See more